A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas

The goal of this study is to evaluate the safety and effectiveness of EVOLVE104 in participants with advanced urothelial and squamous cell carcinomas who have previously taken standard treatment options, have declined or have been ineligible for treatment with these medications. Participants with advanced or metastatic cancer who meet all eligibility criteria may be eligible to participate in the study.

Trial Details

NCT ID
NCT07217171
Phase
PHASE1
Sponsor
EvolveImmune United, Inc
Status
RECRUITING
Cancer Type
Head and Neck Cancer
Interventions
  • EVOLVE104
Locations (sample)
  • Los Angeles, California, United States|34.05223,-118.24368
  • New Haven, Connecticut, United States|41.30815,-72.92816
  • Atlanta, Georgia, United States|33.749,-84.38798
  • Grand Rapids, Michigan, United States|42.96336,-85.66809
  • New York, New York, United States|40.71427,-74.00597

Key Eligibility Criteria

  • Participants must have locally advanced or metastatic cancer with one of the following tumor types: bladder cancer, squamous cell carcinoma of the …
  • Participant must have documented disease progression during or post treatment with standard of care, dependent upon tumor type.
  • The cancer must be measurable by CT scan or MRI.
  • Eastern Cooperative Oncology Group (ECOG) performance status score ≤1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →